WO1998041654A1 - In vitro evolution of oligonucleotides - Google Patents

In vitro evolution of oligonucleotides Download PDF

Info

Publication number
WO1998041654A1
WO1998041654A1 PCT/IL1997/000283 IL9700283W WO9841654A1 WO 1998041654 A1 WO1998041654 A1 WO 1998041654A1 IL 9700283 W IL9700283 W IL 9700283W WO 9841654 A1 WO9841654 A1 WO 9841654A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
mixture
sequence
conditions
oligonucleotide
Prior art date
Application number
PCT/IL1997/000283
Other languages
French (fr)
Inventor
Asher Nathan
Yaron Tikochinski
Original Assignee
Intelligene Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intelligene Ltd. filed Critical Intelligene Ltd.
Priority to AU38621/97A priority Critical patent/AU3862197A/en
Priority to JP54028898A priority patent/JP2001515358A/en
Priority to EP97935737A priority patent/EP0970241A1/en
Publication of WO1998041654A1 publication Critical patent/WO1998041654A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/124—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes based on group I or II introns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules

Definitions

  • the present invention is generally in the field of in vitro evolution of oligonucleotides. More specifically, the present invention concerns a method wherein in vitro evolution is utilized to obtain oligonucleotides featuring a desired property, i.e. binding to a specific agent or having a certain desired catalytic activity.
  • in vitro evolution refers to a method of generating and selecting nucleic acid sequences (which may be DNA or RNA sequences, or sequences comprising both dNTP's and rNTP's, comprising naturally or non-naturally occurring nucleotides) having desired characteristics, without a priori knowing the exact construct of the selected nucleic acid sequence. Typically, it entails production of a huge number of random, or partially random, nucleic acid sequences, then providing the conditions required for selection of those sequences which feature a specific property for example, adding a protein and selecting only those nucleic acid sequences which bind with some affinity to the protein.
  • the selected nucleic acid sequences are then amplified, for example, by polymerase chain reaction (PCR), and the selection and amplification steps are repeated over many cycles, e.g. ranging from 10 to 100, resulting in an enrichment of the reaction mixture by those nucleic acid sequences which feature the desired property. It is at times useful to progressively raise the criteria for selection in each round of a selection and amplification. For example, as the steps of the in vitro evolution proceeds, only species having progressively higher affinity to the desired protein are selected.
  • PCR polymerase chain reaction
  • Ribozymes are typically RNA molecules which have enzyme-like catalytic activities usually associated with cleavage, splicing or ligation of nucleic acid sequences.
  • RNA molecules The typical substrates for ribozymes catalytic activities are RNA molecules, although ribozymes may catalyze reaction in which DNA molecules) are the substrates.
  • ribozymes There are many known ribozymes ranging with respect to the type of their catalytic activity, with respect to the co-factors which are needed for their catalytic activity as well as with respect to the substrates on which their activity is exerted.
  • In vitro evolution is a useful method for preparing and selecting specific types of ribozymes.
  • a method for preparing ribozymes which are active in the presence of an assayed agent, which serves as their co-factor, has been described in co-pending Israel Patent Application No. 119135.
  • Such ribozymes which feature catalytic activity in the presence of an assayed agent, may at times also exert catalytic activity in the presence of a non-assayed agent although at a lower rate or lower affinity. Such non-specific activity may be undesirable for various applications of the ribozymes, e.g. where such ribozymes are used to diagnose the presence of the assayed agent in a medium wherein such nonspecific activity may give rise to false positive results.
  • the potential incomplete specificity of nucleic acid sequence obtained by in vitro evolution which are presumed to be specific, is also a problem for nucleic acids with other specific properties, e.g. such where the specific activity is binding to a specific agent.
  • Oligonucleotide a sequence of nucleotides. May be composed entirely of dNTP's, rNTP's or a combination of both and may comprise non-naturally occurring nucleotides such as 2'-0'-methyl nucleotides or a combination of the above.
  • Oligonucleotide specie - a plurality of oligonucleotide molecules in a mixture featuring essentially the same nucleotide sequence and produced by the amplification step (see below). Each oligonucleotide species has a different sequence.
  • Desired property - a biological property of the oligonucleotide, may be binding to a macromolecule or may be a catalytic activity (see below).
  • SS conditions Selected set of conditions in which the desired property of the oligonucleotide should be evident.
  • examples of such conditions are the presence of an assayed agent (see below), high or low temperature, high or low pH, high or low ionic strength and the like.
  • the purpose of the in vitro evolution method is to produce oligonucleotides featuring the desired property only under SS conditions.
  • Non-selected set of conditions non-SS conditions
  • the purpose of the in vitro evolution method is to remove any oligonucleotides that featured the desired property under these non-selected set of conditions.
  • Functional sequence a sequence of the oligonucleotide which imparts a desired property of the oligonucleotides (examples of desired properties are binding to a macromolecule, or a catalytic activity).
  • Variable sequence - a sequence in the oligonucleotide which is a candidate for evolving into the functional sequence (after carrying out the in vitro evolution method of the invention).
  • the in vitro evolution method of the invention is performed on an initial mixture comprising a plurality of different oligonucleotide sequences, each of which has a different variable sequence.
  • the variable sequence can be prepared utilizing a DNA synthesizer and may be completely random or alternatively may be semi- random or "dopped", i.e. each sequence features X% identity to a sequence of a known dinozyme while (100- X)% of each sequence is random.
  • the variable sequence may constitute a small part, a large part or at times essentially all of the oligonucleotide.
  • Tag sequence a random sequence of oligonucleotides which is not part of said variable sequence and is added to the oligonucleotide for screening purposes only.
  • the randomness of the nucleotide sequence of the tag sequence renders each tag to be dissimilar to a tag sequence of another species of molecules.
  • the tag sequence and the variable sequence are linked via a cleavable sequence (see below).
  • Cleavable sequence - a sequence in the oligonucleotide linking the tag and variable sequence capable of being cleaved, for example, by an enzyme (such as a restriction enzyme) or ribozyme.
  • an enzyme such as a restriction enzyme
  • ribozyme a sequence in the oligonucleotide linking the tag and variable sequence capable of being cleaved, for example, by an enzyme (such as a restriction enzyme) or ribozyme.
  • Positive selection step - a step in the in vitro evolution method in which molecules featuring a specific property under the SS conditions are collected.
  • Negative selection step - a step in the in vitro evolution method in which molecules featuring a desired property under non-selected SS conditions are removed.
  • Amplification step - a step in the in vitro evolution method in which each oligonucleotide molecule is amplified several folds in order to obtain several copies of each molecule.
  • the copies may be identical to the parent oligonucleotides, or may have some modifications which were inserted due to the amplification process (for example mutations inserted during the reverse transcription). This non-perfect accuracy of the amplification process is in fact an advantage in the in vitro evolution method.
  • Examples of amplification techniques are PCR, NASBA, 3SR, SDA, etc.
  • Hybridization under stringent conditions - hybridization under conditions which will give rise to hybridization in the case of homology of the two hybridizing nucleic acid sequences but will not permit hybridization in a case of even a single base mismatch between two sequences.
  • Assayed agent - a molecule the presence of which is to be detected in the sample.
  • molecules include, for example: proteins; peptides; oligopeptides; antibiotics; phosphate nucleotides such as ATP, GTP, cyclic AMP, and others; carbohydrates; lipids; nucleic acid sequences (DNA or RNA sequences); etc.
  • the present invention is directed to a novel method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, which makes use of in vitro evolution.
  • the novelty of the present invention resides in a unique combination of positive and negative selection steps.
  • oligonucleotides which feature the desired property under the selected set of conditions (the "SS conditions") are selected.
  • the negative selection step involves removal of oligonucleotides which feature the desired property under conditions wherein the oligonucleotides are not intended to have their desired properties, i.e. under any condition which is different than the selected condition (the "non- SS conditions").
  • the positive selection step will involve collecting oligonucleotides which feature the desired catalytic activity in the presence of the assayed agent (i.e. said SS conditions are the presence of the assayed agent).
  • the negative selection step will involve removing oligonucleotides which feature the desired catalytic activity also in the presence of an agent other than said specific agent (i.e. said non-SS conditions are the presence of a non-assayed agent).
  • the problem intended to be solved by the present invention is the difficulty in separating between oligonucleotides which feature the desired property only under the SS conditions (for example, only in the presence of a specific assayed agent) and those which feature the desired property both under the SS conditions, as well as under non-SS conditions (e.g. feature the desired property also in the presence of non-assayed agents).
  • the molecules removed during the negative selection step may be collected, and may be used to "fish out", by hybridization, other identical molecules of the same species which should have been removed, but due to the short incubation time did not have a chance to feature the desired property, (for example, catalytic activity).
  • sequences of oligonucleotides which feature catalytic activity both under SS and non-SS conditions (to be removed), and the sequences of the oligonucleotides which feature the desired property only under SS conditions (to be maintained), may be very similar, the difference in sequence being very small relative to the large size of the oligonucleotide, so that it would be practically impossible to distinguish between the two by hybridization.
  • the solution to this problem in accordance with the invention is the addition of a random tag sequence to each of the oligonucleotides in the initial oligonucleotide mixture, so that after amplification all oligonucleotides of the same species (originating from the same parent oligonucleotide) have the same random tag sequence.
  • This tag sequence does not form part of the functional sequence of the nucleotide which is the part which imparts the desired property.
  • the tag sequence is linked to the variable sequence (the candidate for evolving to the functional sequence). While the variable sequence of different oligonucleotide species may be similar (for example since all variable sequences were "doped" from an original known sequence) the tag sequence is completely different from one oligonucleotide species to the other.
  • oligonucleotides featuring the desired property under non-SS conditions are collected, it is possible to cleave the cleavable sequence, and thus collect the tag sequences of the undesired oligonucleotides.
  • These tag sequences which are random, have a very high probability, depending on the size of the tag, of being different in each species of oligonucleotide molecules, and thus may be used to effectively "fish out” complementary tag sequences of other members of the undesired oligonucleotide species. Since the "fishing out", i.e.
  • the present invention is suitable for the production of oligonucleotides which feature a desired property under SS conditions and do not feature the desired property under non- SS conditions, wherein the initial pool of oligonucleotides, on which the in vitro evolution takes place is already known to possess the desired property under SS conditions. All that is necessary, in accordance with said first embodiment is to remove from said initial pool of oligonucleotides those oligonucleotides which feature the desired property also under non- SS conditions.
  • An example of the utilization of the first embodiment of the invention is when starting with a pool of oligonucleotides which are derived (for example by doping or by changing a specific region), from an oligonucleotide having a known desired property, for example, derived from a ribozyme having catalytic activity under SS conditions. It is assumed that the derived oligonucleotides in the original pool (which vary slightly from one another) already have catalytic activity under the SS conditions, so that all that is necessary is to remove from the pool those oligonucleotides having the catalytic activity also under non-SS conditions. Even if as a result that catalytic activity under SS conditions is lowered, this is still tolerable.
  • the method comprises only negative selection steps.
  • the third selected mixture of oligonucleotides can be amplified to obtain a plurality of copies thereof. It is possible to add an amplification step to amplify the oligonucleotides of the first selected mixture. Such an amplification step may yield both oligonucleotides with a sense sequence ("sense oligonucleotides”) as well as oligonucleotides having a complementary, anti- sense sequence ("an -sense oligonucleotides").
  • the amplification of the second group of oligonucleotides may also yield both groups of oligonucleotides (sense oligonucleotides and anti-sense oligonucleotides) and similarly, the collected tag sequences (step (d)) will comprise of both sense tag sequence and anti-sense tag sequences. If the first selected mixture has not been amplified, the hybridization will be between the anti-sense tag sequences and the tag sequences in the original sense oligonucleotides.
  • both sense tag sequences and anti-sense tag sequences may be hybridized to complementary sequences in the oligonucleotides of the amplified first selected mixture (to anti-sense and sense oligonucleotides, respectively).
  • the tag sequence may be a terminal sequence of the oligonucleotides, or the tag sequence may be a non-terminal sequence, constructed in a mid portion of the oligonucleotide.
  • the oligonucleotides featuring the desired properties only under SS conditions and not under non-SS conditions are evolved from a pool of oligo- nucleotides which are not known, a priori, to have the desired property and therefore should be screened also by positive selection steps.
  • a positive selection step comprising applying said selected set of conditions and separating between the oligonucleotides which feature said desired property and those which do not, to obtain a first selected mixture comprising a first group of oligonucleotides featuring said desired property under said selected set of conditions;
  • an amplification step comprising amplifying said first group of oligonucleotides in said first selected mixture to produce a plurality of copies of each of said first group of oligonucleotides to obtain a first amplified mixture;
  • a negative selection step comprising: (bca) applying a second set of conditions, being different than said selected set of conditions, and separating between a second group of oligonucleotides which do not feature the desired property under said second set of condi- tions and a third group of oligonucleotides featuring said desired property under said second set of conditions, to obtain a second selected mixture comprising said second group of oligonucleotides and a third selected mixture comprising said third group of oligonucleotides; (bcb) amplifying said third group of oligonucleotides in said third selected mixture to produce a plurality of copies of each of said third group of oligonucleotides to obtain a second amplified mixture;
  • the collected tag sequences which are contacted with the second selected mixture may comprise, similarly as pointed out above, of both sense and anti-sense tag sequences which then hybridize to anti- sense or sense oligonucleotides respectively, of the second selected mixture.
  • Anti-sense oligonucleotides may be present in the second selected mixture, again similarly as above, following an optional amplification step of the second selected mixture.
  • the positive selection step should precede the negative selection step. It is preferable that in the positive selection step of each consecutive cycle, the conditions become more and more stringent, for example, shorter assay times, harsher sample preparation conditions etc.; while in the negative selection step conditions become less stringent allowing even those oligonucleotides with a very small activity in the conditions of the negative selection step to exert their activity (and thus to be removed), for example by utilizing longer incubation times, conditions which more closely resemble those in the positive selection step, etc. Where the negative selection step is repeated a plurality of times, each step or several steps may be performed under a different set of non-SS conditions. For example, where said SS conditions include the presence in the medium of a certain protein, the non-SS conditions which are applied in the negative selection steps may be the presence of different proteins, each one of a plurality of different proteins being present in a different negative selection step.
  • a specific example for said desired property is catalytic activity, similar to catalytic activity featured by ribozymes.
  • Another desired property is binding of the oligonucleotide to a protein for the preparation of aptamers.
  • the SS conditions may for example be temperature, ionic strength, acidity, and preferably is the presence of a certain agent in the medium. The latter is useful particularly for diagnostic purposes.
  • Said assayed agent may for example be a nucleic acid sequence, a protein or any other macromolecule.
  • the variable sequence may be random but in accordance with a preferred embodiment of the invention, the variable sequence is doped, i.e. having a certain degree of similarity (for example 70%) to a sequence having a known desired property, for example, to the sequence of a ribozyme.
  • Separation between various groups of oligonucleotides for example between those having a catalytic activity in the SS conditions and those not having such catalytic activity may be carried out by any of a variety of known ways.
  • the separation may be based on separating between soluble and immobilized oligonucleotides.
  • the catalytic activity is for example cleavage
  • all oligonucleotides in the initial mixture of different oligonucleotides can be, a priori, immobilized onto a solid support and those which are catalytically active and are able to perform cleavage in cis are then released into the medium.
  • oligonucleotides which, when catalytically active are able to ligate to a substrate oligonucleotide which is immobilized on a solid support.
  • active oligonucleotides will become immobilized, and inactive oligonucleotides will remain soluble.
  • Aptamers can be separated utilizing their binding properties to immobilized substrates, such as to immobilized antibodies.
  • Separation between oligonucleotides that hybridize to the collected tag sequences and those which do not, can be performed, for example, by immobilizing the tag sequences on a solid support and then separating between the immobilized and unimmobilized oligonucleotides.
  • the separation may be based on the some designed properties of the tag sequences. For example, it is possible to construct a tag sequence which is partially random but has a site, which when double-stranded, forms a restriction site.
  • a restriction enzyme is added and then only the oligonucleotides which hybridize with a tag sequence (the hybridization is either between an anti- sense oligonucleotide to a sense tag sequence or between a sense oligonucleotide and an anti-sense tag sequence) will have a restriction site and will be restricted by the enzyme. Cleavage of these oligonucleotides will avoid their amplification in subsequent steps since the primer sequences at both ends of the oligonucleotides have been separated by the cleavage.
  • the tag sequences which are collected in the negative selection step are complementary to the tag sequences in the mixture from which oligonucleotides should be "fished out".
  • the complementary tag sequence used for fishing out is preferably a DNA sequence.
  • the oligonucleotide to be fished out is a DNA oligonucleotide, e.g. being a catalytic DNA molecule or an aptamer
  • the complementary tag sequence used for fishing out of such oligonucleotides is an RNA sequence.
  • a specific utility of the method of the invention is in preparing ribozymes which are capable of featuring their catalytic activity only when they have a complete structure (hereinafter: “full form "), and cannot feature the activity when nicked (i.e. the sequence is non-continuous), when having a missing portion or when attached to a redundant sequence (which is a sequence that should be removed in order to render the ribozyme active) (hereinafter: “incomplete form ").
  • Such ribozymes can be used as part of a ribozyme amplification cascade, for example, as that described in PCT Application No. PCT/US96/02380 and corresponding Israel Patent Applications Nos. 112799 and 115772 the context of which are being incorporated herein by reference.
  • a first, initiation ribozyme once a first, initiation ribozyme has been produced, for example due to the presence of an assayed agent in the medium, it can activate other, initially inactive ribozymes, which in turn activate further inactive ribozymes, in a self-amplificatory positive feed-back manner, which produces in a very short time an easily detectable signal.
  • the initially inactive ribozyme is either nicked, has a missing portion or comprises a nick and a redundant sequence, and only upon ligation, gap filling or splicing, respectively, it becomes catalytically active, and may in turn activate other ribozymes in the amplification cascade.
  • the invention provides in accordance with this embodiment an in vitro evolution method for obtaining oligonucleotides which feature a catalytic activity, but which do not feature the catalytic activity when being defective by having a nick or missing a portion in their sequence, the method comprising: (a) preparing a mixture of different oligonucleotides each of which comprises a tag sequence and at least one variable sequence, the variable sequence being a candidate sequence for evolving into a sequence which together with a conserved sequence, identical in all oligonucleotides in the mixture, will feature the catalytic activity; the variable sequence and the tag sequence being different in different oligonucleotides in the mixture, the variable sequence and the tag sequence being linked by at least one cleavable sequence;
  • step (b) processing the oligonucleotide mixture of step (a), in two different manners so as to give rise, together with an oligonucleotide which comprise said conserved sequence, two oligonucleotide constructs, for each of the oligonucleotides in said mixture, the constructs consisting of:
  • step (ba) a first oligonucleotide construct comprising the oligonucleotide obtained in step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence, the construct being incomplete by having a nick or a missing portion, and
  • a second oligonucleotide construct comprising the oligonucleotides of step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence without a nick or a missing portion;
  • a negative selection step comprising: (ca) contacting said first oligonucleotide constructs with a substrate for catalytic activity under conditions enabling said catalytic activity and removing oligonucleotide constructs which do not feature said catalytic activity thereby obtaining a first selected mixture; (cb) amplifying said first selected mixture to obtain a first amplified mixture comprising a plurality of copies of each oligonucleotide constructs;
  • step (e) amplifying said second selected mixture to obtain a second amplified mixture comprising a plurality of copies of each oligonucleotide construct; (f) contacting the collected tag sequences obtained from step (cc) with the second amplified mixture under stringent conditions of hybridization and removing hybridized oligonucleotide constructs from other oligonucleotide constructs of the amplified selected mixture, thereby obtaining a third selected mixture of oligonucleotide constructs featuring said catalytic activity and being essentially devoid of oligonucleotides which feature catalytic activity when present in nicked form, when missing a portion, or containing a nick together with a redundant portion.
  • the catalytic activity of the oligonucleotides according to this specific embodiment may be either ligation, splicing, cleavage, gap filling, kinase-like activity, biotynilation and any other catalytic activity.
  • Fig. 1 shows a schematic representation of the method of the invention for preparing an oligonucleotide which features catalytic activity only in the presence of an assayed agent (Fig. 1 A shows the initial steps of the method and Fig. IB subsequent steps); and
  • Fig. 2 shows a schematic representation of a method for preparing oligonucleotides which feature catalytic activity only when present in a full, i.e. non-defective form.
  • DNA sequences are represented by a straight line and RNA sequences by a wavy line.
  • Two complementary sequences are marked by the same letters one of them also marked with an apostrophe ('"").
  • Example 1 In vitro evolution where the selected condition is the presence of an assayed agent i. Preparing random panel of nucleic acid sequences (1)
  • a panel of DNA oligonucleotides is prepared on a standard nucleic acid synthesizer using a program for generating desired sequences.
  • a typical oligonucleotide is shown in Fig. 1, (1) and comprises a promoter (P) of about 20 bases, a substrate sequence S which can be cleaved in cis by a catalytically active oligonucleotide, a first primer for PCR amplification (PCR1), a first restriction site C x of about 4-8 bases, a random tag (TAG) sequence of about 15 bases, a second restriction site C 2 of about 4-8 bases (both and C 2 sequences are constant and not random), a variable sequence (V) of 50-8000 b.p. averaging at 100, the variable sequence being a candidate for evolving to a functional sequence and a second PCR primer sequence (PCR2).
  • P promoter
  • substrate sequence S which can be cleaved in cis by a catalytically active oligonucleotide
  • PCR1 first primer for PCR amplification
  • TAG random tag
  • V variable sequence
  • V variable sequence of 50-8000 b.
  • variable sequence may be a sequence derived from a sequence known to have the desired function, e.g. catalytic activity. For example, it may be a sequence obtained by doping the known sequence, at a certain degree of randomness, with other nucleic acid residues than in the original sequence. If the variable sequence is obtained by doping of a functional sequence, there may be some degree of similarity in the variable sequence between different oligonucleotides in a mixture of such oligonucleotides.
  • DNA sequences of i. above are transcribed, using a primer with biotin (B) at the 5' end (2).
  • the biotin is then allowed to react with avidin which is present on a solid support, such as Strepravidin beads (SA), so that each oligonucleotide of the panel becomes immobilized onto a solid support (3).
  • SA Strepravidin beads
  • the specific assayed agent which is a protein (Pro) is then added to the reaction mixture (4(a)).
  • Magnesium and/or other co-factors required for catalytic activity are then added to the reaction mixture in order to allow for the catalytic cis cleavage activity of the variable sequences of the oligonucleotides on substrate sequence S.
  • oligonucleotide sequences in the medium may be divided into three classes, as shown (4(b)):
  • the last step of the positive selection comprises collecting of those oligonucleotides which were freed from the immobilized beads (Class i and Class ii).
  • protein attached to the oligonucleotides can be removed by denaturation through heating or by phenol extraction followed by chloroform extraction.
  • step 4 Sequences collected in step 4 above are reversed transcribed and amplified by PCR. Since substrate sequence S was cleaved (step 4b) this sequence should be reconstructed by using, both in the case of reverse transcription and of PCR, primers which contain the sequence of the cleaved substrate and thus the amplified and reconstructed product is again identical to (1).
  • the amplified products are transcribed, bound to biotin and attached to a solid support as specified above (step 6).
  • the amplified and immobilized oligonucleotides of step 6 are subjected to a negative selection step.
  • the catalytic activity is determined either with no assayed agent, or in the presence of a non- assayed agent, which, although not identical, closely resembles the assayed agent (preferably such a non-assay agent may be one which can be encountered by the oligonucleotide in the assayed conditions); the non- assayed agent illustrated here is a protein - Pro' (step 7a); magnesium and/or other co-factors required for catalytic activity are added (step 7b).
  • the oligonucleotides released to the medium by cleavage of the substrate sequence S belong to three classes:
  • Both Classes i. and ii. are collected (step 7c) and the protein is removed (step 7d).
  • the sequences are reversed transcribed and amplified by PCR in order to produce a double-stranded construct (step 8).
  • Suitable restriction enzymes are added in order to cleave sequences and C 2 , one cleavage site forming a blunt end and one a sticky end (step 9).
  • the sticky end is completed with a biotinated nucleotide and then the separated TAG sequence is immobilized on a solid support (through an immobilized avidin) and denaturated so that there remains a single-stranded denaturated immobilized tag sequence.
  • the immobilized tag sequences of step 10 are brought into contact with oligonucleotides collected of step 4(b) (Class i and Class ii) (step 11). Molecules of said group which hybridize with the immobilized TAG sequence are removed (step 12) so there remain only molecules which feature cleavage in the presence of an assayed agent (Pro) and do not feature cleavage activity without any agent or in the presence of a non- assayed agent (Pro').
  • oligonucleotides obtained in step 11 are subjected again to all preceding steps for 2-1000 cycles, preferably 10-100 cycles, most preferably 20-30 cycles.
  • Fig. 2 shows another embodiment of the in vitro evolution method of the invention. The purpose of the method disclosed in Fig. 2 is to produce oligonucleotides which are devoid of catalytic activity in an incomplete form and are capable of catalytic activity only when in a complete form.
  • An oligonucleotide which is in an incomplete form includes an oligonucleotide with a nick in its sequence, an oligonucleotide with a missing nucleotide segment, an oligonucleotide with a nick and with a redundant sequence, etc.
  • a mixture of different DNA sequences 1 is prepared (step a) featuring (from 5' ⁇ 3'): immobilization moiety (such as a bead), linked to a promoter (PROM), a first PCR primer (PCR1'), a variable sequence V,', a cleavage sequence Cj, tag sequence (TAG), a cleavable sequence C 2 , another variable sequence V 2 ' and a second PCR primer (PCR2').
  • V x ' and V 2 ' are both sequences which are complementary to doped sequences from an original Group I ribozyme (hereinafter "known ribozyme") and comprise together only a part (for example, half) complementary to that known ribozyme.
  • the TAG sequence between V, and V 2 ' is present within a sequence coding for an intron of the known ribozyme and thus does not interfere with the activity of the transcript.
  • DNA sequence 1 is processed by two routes: First by Route I (left) which brings about production of nicked oligonucleotides for negative selection purposes and second by Route II (right) which brings to production of complete oligonucleotides.
  • RNA oligonucleotide 3 comprising a sequence denoted "CONS " which is a conserved sequence of the known ribozyme required to complete the doped parts V x and V 2 (transcribed from V/ and V 2 ') to a complete ribozyme, (so that V x +V 2 +CONS constitute together a construct resembling that of the known ribosome wherein the 5 '-end part (V,+V 2 ) is doped (as compared to a known ribozyme) and the 3'-end part (CONS) is identical to a known ribozyme).
  • CONS a conserved sequence of the known ribozyme required to complete the doped parts V x and V 2 (transcribed from V/ and V 2 ') to a complete ribozyme, (so that V x +V 2 +CONS constitute together a construct resembling that of the known ribosome wherein the 5 '-end part
  • Transcript 2 and oligonucleotide 3 hybridize to form together construct 4, (step c) which is essentially similar to the known ribozyme (with doped V, and V 2 sequences and conserved CONS) but having a nick 5.
  • the purpose of the method of the invention according to this embodiment is to remove all species of oligonucleotides which feature catalytic activity despite having a nick - i.e. to remove all species represented by construct 4.
  • Oligonucleotides which serve as substrates for ligation and which are immobilized to a solid support 6 are then added to construct 4, and the two are allowed to ligate (step d).
  • the construct 4 fall into two classes (step e): Class (1) constructs which were able to ligate to the immobilized substrate and are thus collected and Class (2) constructs which were not able to ligate, remain soluble and are thus removed. Separation can also be carried out, mutatis mutandis, utilizing cleavage activity, gap filling, splicing activities, etc.
  • the collected constructs are reverse transcribed and amplified utilizing PCR primers PCR1 and PCR2 (the CONS sequence is thus not amplified) and the TAG sequence are removed therefrom, for example by restriction enzymes (step f).
  • the TAG is then immobilized to a solid support to yield immobilized tag 11, which will be used to "fish out” species which should be removed (step g).
  • step (f) of route II (which is identical to DNA sequence 1) or the DNA sequence 1 itself is brought into contact with DNA oligonucleotide 7 having PCR2 sequence complementary to PCR2', CONS' of coding for a conserved sequence as described above and PCR3 sequence which complements to a third PCR primer (step h).
  • the two are allowed to hybridize and in the presence of DNA polymerase and nucleotides give rise to double-stranded DNA construct 8 (step i) which in the presence of T 7 polymerase brings to the production of transcript 9 (step j).
  • Transcript 9 is in essence identical to construct 4 but it does not have a nick.
  • Oligonucleotide substrate 6 is then added. Those transcripts 9 which were able to ligate to substrate 6 are maintained (class 1) and those which were not able to are removed (class 2) (step k). The maintained transcripts are reverse transcribed and PCR amplified to give transcripts 10 (step 1).
  • Transcripts 10 are contacted with immobilized TAG 11 obtained in step g in a negative selection step (step m). Those transcripts 10 which hybridize with the TAG are then removed (step n).
  • step m a negative selection step which removes oligonucleotides which are catalytically active when present with a nick and a positive selection step which selects for oligonucleotides showing catalytic activity without a nick.

Abstract

The present invention concerns a method for in vitro evolution of oligonucleotides. In the method of the invention the negative selection step, in which undesired oligonucleotides are removed, utilizes a unique random tag sequence attached to the evolving oligonucleotides which enables to eliminate, by hybridization, undesired oligonucleotides.

Description

IN VITRO EVOLUTION OF OLIGONUCLEOTIDES
FIELD OF THE INVENTION
The present invention is generally in the field of in vitro evolution of oligonucleotides. More specifically, the present invention concerns a method wherein in vitro evolution is utilized to obtain oligonucleotides featuring a desired property, i.e. binding to a specific agent or having a certain desired catalytic activity.
BACKGROUND OF THE INVENTION
The term "in vitro evolution ", refers to a method of generating and selecting nucleic acid sequences (which may be DNA or RNA sequences, or sequences comprising both dNTP's and rNTP's, comprising naturally or non-naturally occurring nucleotides) having desired characteristics, without a priori knowing the exact construct of the selected nucleic acid sequence. Typically, it entails production of a huge number of random, or partially random, nucleic acid sequences, then providing the conditions required for selection of those sequences which feature a specific property for example, adding a protein and selecting only those nucleic acid sequences which bind with some affinity to the protein. The selected nucleic acid sequences are then amplified, for example, by polymerase chain reaction (PCR), and the selection and amplification steps are repeated over many cycles, e.g. ranging from 10 to 100, resulting in an enrichment of the reaction mixture by those nucleic acid sequences which feature the desired property. It is at times useful to progressively raise the criteria for selection in each round of a selection and amplification. For example, as the steps of the in vitro evolution proceeds, only species having progressively higher affinity to the desired protein are selected.
In vitro selection methodologies to probe RNA function and structures are summarized in a review by Conrad, R.C., Molecular Diversity 1:69-78 (1995) and have been studied in models for autocatalytic replication of RNA by Giver et al. (G.R. Fleischaker et al. (Editor), Self- Production of Supramolecular Structures 137-146, (1994), Klewer Academic Publishers). Most in vitro evolution methods have been used either to prepare catalytically active ribozymes, and then the selected property was the ribozymes' catalytic activity, or for the preparation of aptamers which are nucleotide sequences capable of binding proteins, for example antibodies, and in such a case the selected property is binding (Ellington, A., Current Biology, 4(5):427-429 (1994); Ellington A., and Conard R., Biochem. An. Rev. , 1:185-215 (1995)). Ribozymes are typically RNA molecules which have enzyme-like catalytic activities usually associated with cleavage, splicing or ligation of nucleic acid sequences. The typical substrates for ribozymes catalytic activities are RNA molecules, although ribozymes may catalyze reaction in which DNA molecules) are the substrates. There are many known ribozymes ranging with respect to the type of their catalytic activity, with respect to the co-factors which are needed for their catalytic activity as well as with respect to the substrates on which their activity is exerted. In vitro evolution is a useful method for preparing and selecting specific types of ribozymes. A method for preparing ribozymes which are active in the presence of an assayed agent, which serves as their co-factor, has been described in co-pending Israel Patent Application No. 119135. Such ribozymes which feature catalytic activity in the presence of an assayed agent, may at times also exert catalytic activity in the presence of a non-assayed agent although at a lower rate or lower affinity. Such non-specific activity may be undesirable for various applications of the ribozymes, e.g. where such ribozymes are used to diagnose the presence of the assayed agent in a medium wherein such nonspecific activity may give rise to false positive results. The potential incomplete specificity of nucleic acid sequence obtained by in vitro evolution which are presumed to be specific, is also a problem for nucleic acids with other specific properties, e.g. such where the specific activity is binding to a specific agent.
It would have been highly desirable to have an in vitro method which would allow to prepare oligonucleotides not featuring said false positive results.
GLOSSARY
The following terms may be used at times throughout the specification:
Oligonucleotide - a sequence of nucleotides. May be composed entirely of dNTP's, rNTP's or a combination of both and may comprise non-naturally occurring nucleotides such as 2'-0'-methyl nucleotides or a combination of the above.
Oligonucleotide specie - a plurality of oligonucleotide molecules in a mixture featuring essentially the same nucleotide sequence and produced by the amplification step (see below). Each oligonucleotide species has a different sequence.
Desired property - a biological property of the oligonucleotide, may be binding to a macromolecule or may be a catalytic activity (see below).
Catalytic activity - an enzyme-like activity featured by the functional sequence including all possible catalytic activities of catalytic nucleic acid sequences (see below), such as cleavage, ligation, splicing-out (cleaving both ends of a short nucleic acid sequence to remove it from a longer sequence and ligating the ends of the cut), splicing-in (cleaving open a nucleic acid sequence, inserting another short nucleic acid sequence and ligating the ends of the cut), rearrangement, as well as additional catalytic activities such as phosphorylation, kinase like activity, addition or removal of other chemical moieties, biotinilation, gap filling of missing nucleotides, polymerization, etc.
Selected set of conditions (SS conditions) - conditions in which the desired property of the oligonucleotide should be evident. Examples of such conditions are the presence of an assayed agent (see below), high or low temperature, high or low pH, high or low ionic strength and the like. The purpose of the in vitro evolution method is to produce oligonucleotides featuring the desired property only under SS conditions.
Non-selected set of conditions (non-SS conditions) - conditions which are different than the SS condition. The purpose of the in vitro evolution method is to remove any oligonucleotides that featured the desired property under these non-selected set of conditions.
Functional sequence - a sequence of the oligonucleotide which imparts a desired property of the oligonucleotides (examples of desired properties are binding to a macromolecule, or a catalytic activity).
Variable sequence - a sequence in the oligonucleotide which is a candidate for evolving into the functional sequence (after carrying out the in vitro evolution method of the invention). The in vitro evolution method of the invention is performed on an initial mixture comprising a plurality of different oligonucleotide sequences, each of which has a different variable sequence. The variable sequence can be prepared utilizing a DNA synthesizer and may be completely random or alternatively may be semi- random or "dopped", i.e. each sequence features X% identity to a sequence of a known dinozyme while (100- X)% of each sequence is random. The variable sequence may constitute a small part, a large part or at times essentially all of the oligonucleotide.
Tag sequence - a random sequence of oligonucleotides which is not part of said variable sequence and is added to the oligonucleotide for screening purposes only. The randomness of the nucleotide sequence of the tag sequence renders each tag to be dissimilar to a tag sequence of another species of molecules. The tag sequence and the variable sequence are linked via a cleavable sequence (see below).
Cleavable sequence - a sequence in the oligonucleotide linking the tag and variable sequence capable of being cleaved, for example, by an enzyme (such as a restriction enzyme) or ribozyme.
Positive selection step - a step in the in vitro evolution method in which molecules featuring a specific property under the SS conditions are collected.
Negative selection step - a step in the in vitro evolution method in which molecules featuring a desired property under non-selected SS conditions are removed.
Amplification step - a step in the in vitro evolution method in which each oligonucleotide molecule is amplified several folds in order to obtain several copies of each molecule. The copies may be identical to the parent oligonucleotides, or may have some modifications which were inserted due to the amplification process (for example mutations inserted during the reverse transcription). This non-perfect accuracy of the amplification process is in fact an advantage in the in vitro evolution method. Examples of amplification techniques are PCR, NASBA, 3SR, SDA, etc. Hybridization under stringent conditions - hybridization under conditions which will give rise to hybridization in the case of homology of the two hybridizing nucleic acid sequences but will not permit hybridization in a case of even a single base mismatch between two sequences.
Assayed agent - a molecule the presence of which is to be detected in the sample. Such molecules include, for example: proteins; peptides; oligopeptides; antibiotics; phosphate nucleotides such as ATP, GTP, cyclic AMP, and others; carbohydrates; lipids; nucleic acid sequences (DNA or RNA sequences); etc.
GENERAL DESCRIPTION OF THE INVENTION
The present invention is directed to a novel method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, which makes use of in vitro evolution. The novelty of the present invention resides in a unique combination of positive and negative selection steps. In the positive selection steps, oligonucleotides which feature the desired property under the selected set of conditions (the "SS conditions") are selected. The negative selection step involves removal of oligonucleotides which feature the desired property under conditions wherein the oligonucleotides are not intended to have their desired properties, i.e. under any condition which is different than the selected condition (the "non- SS conditions").
For example, where it is desired that the oligonucleotides will perform a certain catalytic activity (i.e. feature a desired property) under SS conditions, e.g. in the presence of a certain assayed agent, the positive selection step will involve collecting oligonucleotides which feature the desired catalytic activity in the presence of the assayed agent (i.e. said SS conditions are the presence of the assayed agent). The negative selection step will involve removing oligonucleotides which feature the desired catalytic activity also in the presence of an agent other than said specific agent (i.e. said non-SS conditions are the presence of a non-assayed agent). The problem intended to be solved by the present invention, is the difficulty in separating between oligonucleotides which feature the desired property only under the SS conditions (for example, only in the presence of a specific assayed agent) and those which feature the desired property both under the SS conditions, as well as under non-SS conditions (e.g. feature the desired property also in the presence of non-assayed agents). Many times, the molecules which feature the desired property under non-SS conditions, do so at a very low efficiency; thus a negative selection step in which oligonucleotides which feature the desired property under non-SS conditions are identified (by their catalytic activity) and removed, may require extremely prolonged incubation times, rendering impractical the whole process of in vitro evolution (which requires multiple cycles of negative selection steps). If regular incubation times are used, there is a likelihood that only a small percentage of the molecules making up a specific oligonucleotide species which should be removed will actually feature the desired property under non-SS conditions within the regular incubation time. This can result in incomplete removal of undesired molecules in the negative selection step, and may eventually lead, when the oligonucleotides are used for diagnostic purposes, to false negative results. In principle, the molecules removed during the negative selection step may be collected, and may be used to "fish out", by hybridization, other identical molecules of the same species which should have been removed, but due to the short incubation time did not have a chance to feature the desired property, (for example, catalytic activity). However, the sequences of oligonucleotides which feature catalytic activity both under SS and non-SS conditions (to be removed), and the sequences of the oligonucleotides which feature the desired property only under SS conditions (to be maintained), may be very similar, the difference in sequence being very small relative to the large size of the oligonucleotide, so that it would be practically impossible to distinguish between the two by hybridization.
The solution to this problem in accordance with the invention, is the addition of a random tag sequence to each of the oligonucleotides in the initial oligonucleotide mixture, so that after amplification all oligonucleotides of the same species (originating from the same parent oligonucleotide) have the same random tag sequence. This tag sequence, does not form part of the functional sequence of the nucleotide which is the part which imparts the desired property. The tag sequence is linked to the variable sequence (the candidate for evolving to the functional sequence). While the variable sequence of different oligonucleotide species may be similar (for example since all variable sequences were "doped" from an original known sequence) the tag sequence is completely different from one oligonucleotide species to the other.
Thus, when following a negative selection step, oligonucleotides featuring the desired property under non-SS conditions are collected, it is possible to cleave the cleavable sequence, and thus collect the tag sequences of the undesired oligonucleotides. These tag sequences, which are random, have a very high probability, depending on the size of the tag, of being different in each species of oligonucleotide molecules, and thus may be used to effectively "fish out" complementary tag sequences of other members of the undesired oligonucleotide species. Since the "fishing out", i.e. elimination process, is based only on the hybridization of the unique tag sequence (which is different than the tag sequences of the other species), the fact that the variable sequence of the oligonucleotides which are to be removed is very similar to the variable sequence of the oligonucleotides which should be maintained, does not affect the selection process.
By a first embodiment the present invention is suitable for the production of oligonucleotides which feature a desired property under SS conditions and do not feature the desired property under non- SS conditions, wherein the initial pool of oligonucleotides, on which the in vitro evolution takes place is already known to possess the desired property under SS conditions. All that is necessary, in accordance with said first embodiment is to remove from said initial pool of oligonucleotides those oligonucleotides which feature the desired property also under non- SS conditions. An example of the utilization of the first embodiment of the invention is when starting with a pool of oligonucleotides which are derived (for example by doping or by changing a specific region), from an oligonucleotide having a known desired property, for example, derived from a ribozyme having catalytic activity under SS conditions. It is assumed that the derived oligonucleotides in the original pool (which vary slightly from one another) already have catalytic activity under the SS conditions, so that all that is necessary is to remove from the pool those oligonucleotides having the catalytic activity also under non-SS conditions. Even if as a result that catalytic activity under SS conditions is lowered, this is still tolerable. In accordance with said first embodiment the method comprises only negative selection steps.
Thus in accordance with a first embodiment of the invention there is provided an in vitro evolution method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, and which do not feature the desired property under a set of conditions different than the selected set of conditions, said desired property being imparted by a functional sequence of said oligonucleotides, the method comprising:
(a) preparing a mixture of different oligonucleotides each comprising a variable sequence, derived from a functional sequence of an oligonucleo- tide, known to feature said desired property under a selected set of conditions, and a tag sequence; said variable sequence and said tag sequence being different in different oligonucleotides in the mixture, said variable sequence and said tag sequences being linked by at least one cleavable sequence; (b) applying a second set of conditions being different than said selected set of conditions and separating between a first group of oligonucleotides which do not feature the desired property under said second set of conditions and a second group of oligonucleotides featuring said desired property under said second set of conditions, to obtain a first selected mixture comprising said first group of oligonucleotides and a second selected mixture comprising said second group of oligonucleotides; (c) amplifying said second group of oligonucleotides in said second selected mixture to produce a plurality of copies of each of said second group of oligonucleotides to obtain a first amplified mixture;
(d) cleaving the cleavable sequence of the oligonucleotides in the first amplified mixture, separating between the variable and the tag sequences and collecting the tag sequences;
(e) contacting the collected tag sequences with the first selected mixture under stringent conditions of hybridization and removing hybridized oligonucleotides from other oligonucleotides of the second mixture; thereby obtaining a third selected mixture of oligonucleotides essentially devoid of oligonucleotides which feature the desired property under said second set of conditions.
As will be appreciated, the third selected mixture of oligonucleotides can be amplified to obtain a plurality of copies thereof. It is possible to add an amplification step to amplify the oligonucleotides of the first selected mixture. Such an amplification step may yield both oligonucleotides with a sense sequence ("sense oligonucleotides") as well as oligonucleotides having a complementary, anti- sense sequence ("an -sense oligonucleotides"). The amplification of the second group of oligonucleotides (step (c)) may also yield both groups of oligonucleotides (sense oligonucleotides and anti-sense oligonucleotides) and similarly, the collected tag sequences (step (d)) will comprise of both sense tag sequence and anti-sense tag sequences. If the first selected mixture has not been amplified, the hybridization will be between the anti-sense tag sequences and the tag sequences in the original sense oligonucleotides. In case the first selected mixture has been amplified, both sense tag sequences and anti-sense tag sequences may be hybridized to complementary sequences in the oligonucleotides of the amplified first selected mixture (to anti-sense and sense oligonucleotides, respectively). It should be noted that the tag sequence may be a terminal sequence of the oligonucleotides, or the tag sequence may be a non-terminal sequence, constructed in a mid portion of the oligonucleotide. In accordance with a second embodiment of the invention the oligonucleotides featuring the desired properties only under SS conditions and not under non-SS conditions are evolved from a pool of oligo- nucleotides which are not known, a priori, to have the desired property and therefore should be screened also by positive selection steps.
Thus in accordance with the second embodiment of the invention there is provided an in vitro evolution method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, and which do not feature the desired property under a set of conditions different than the selected set of conditions, said desired property being imparted by a functional sequence of said oligonucleotides, the method comprising:
(a) preparing a mixture of different oligonucleotides each of which comprises a variable sequence being a candidate for said functional sequence and a tag sequence, said variable sequence and said tag sequence being different in different oligonucleotides in the mixture, the variable sequence and the tag sequence being linked by at least one cleavable sequence;
(b) processing the mixture through positive and negative selection steps, there being at least one positive selection step and at least one negative selection step, these steps comprising:
(ba) a positive selection step comprising applying said selected set of conditions and separating between the oligonucleotides which feature said desired property and those which do not, to obtain a first selected mixture comprising a first group of oligonucleotides featuring said desired property under said selected set of conditions;
(bb) an amplification step comprising amplifying said first group of oligonucleotides in said first selected mixture to produce a plurality of copies of each of said first group of oligonucleotides to obtain a first amplified mixture;
(be) a negative selection step comprising: (bca) applying a second set of conditions, being different than said selected set of conditions, and separating between a second group of oligonucleotides which do not feature the desired property under said second set of condi- tions and a third group of oligonucleotides featuring said desired property under said second set of conditions, to obtain a second selected mixture comprising said second group of oligonucleotides and a third selected mixture comprising said third group of oligonucleotides; (bcb) amplifying said third group of oligonucleotides in said third selected mixture to produce a plurality of copies of each of said third group of oligonucleotides to obtain a second amplified mixture;
(bcc) cleaving the cleavable sequence of the oligonucleotides in the second amplified mixture, separating between the variable and the tag sequences and collecting the tag sequences;
(bed) contacting the collected tag sequences with the second selected mixture under stringent conditions of hybridization and removing hybridized oligonucleotides from other oligonucleotides of the second mixture, thereby obtaining a fourth selected mixture of oligonucleotides essentially devoid of oligonucleotides which feature the desired property under said second set of conditions; where said positive selection step precedes said negative selection step, said positive selection step is applied on said mixture prepared in step (a) and said negative selection step is applied on said first amplified mixture; and where said negative selection step precedes said positive selection step, said negative selection step is applied on said mixture obtained in step (a) and said positive selection step is applied on said fourth mixture.
The collected tag sequences which are contacted with the second selected mixture (step (bed)) may comprise, similarly as pointed out above, of both sense and anti-sense tag sequences which then hybridize to anti- sense or sense oligonucleotides respectively, of the second selected mixture. Anti-sense oligonucleotides may be present in the second selected mixture, again similarly as above, following an optional amplification step of the second selected mixture.
Preferably, the positive selection step should precede the negative selection step. It is preferable that in the positive selection step of each consecutive cycle, the conditions become more and more stringent, for example, shorter assay times, harsher sample preparation conditions etc.; while in the negative selection step conditions become less stringent allowing even those oligonucleotides with a very small activity in the conditions of the negative selection step to exert their activity (and thus to be removed), for example by utilizing longer incubation times, conditions which more closely resemble those in the positive selection step, etc. Where the negative selection step is repeated a plurality of times, each step or several steps may be performed under a different set of non-SS conditions. For example, where said SS conditions include the presence in the medium of a certain protein, the non-SS conditions which are applied in the negative selection steps may be the presence of different proteins, each one of a plurality of different proteins being present in a different negative selection step.
A specific example for said desired property is catalytic activity, similar to catalytic activity featured by ribozymes. Another desired property is binding of the oligonucleotide to a protein for the preparation of aptamers. The SS conditions may for example be temperature, ionic strength, acidity, and preferably is the presence of a certain agent in the medium. The latter is useful particularly for diagnostic purposes. Said assayed agent may for example be a nucleic acid sequence, a protein or any other macromolecule. The variable sequence may be random but in accordance with a preferred embodiment of the invention, the variable sequence is doped, i.e. having a certain degree of similarity (for example 70%) to a sequence having a known desired property, for example, to the sequence of a ribozyme.
Separation between various groups of oligonucleotides, for example between those having a catalytic activity in the SS conditions and those not having such catalytic activity may be carried out by any of a variety of known ways. For example, the separation may be based on separating between soluble and immobilized oligonucleotides. Where the catalytic activity is for example cleavage, all oligonucleotides in the initial mixture of different oligonucleotides can be, a priori, immobilized onto a solid support and those which are catalytically active and are able to perform cleavage in cis are then released into the medium. Another example are oligonucleotides which, when catalytically active are able to ligate to a substrate oligonucleotide which is immobilized on a solid support. In this example active oligonucleotides will become immobilized, and inactive oligonucleotides will remain soluble.
Aptamers can be separated utilizing their binding properties to immobilized substrates, such as to immobilized antibodies.
Separation between oligonucleotides that hybridize to the collected tag sequences and those which do not, can be performed, for example, by immobilizing the tag sequences on a solid support and then separating between the immobilized and unimmobilized oligonucleotides. Alternatively, the separation may be based on the some designed properties of the tag sequences. For example, it is possible to construct a tag sequence which is partially random but has a site, which when double-stranded, forms a restriction site. After hybridization with the collected tag sequences, a restriction enzyme is added and then only the oligonucleotides which hybridize with a tag sequence (the hybridization is either between an anti- sense oligonucleotide to a sense tag sequence or between a sense oligonucleotide and an anti-sense tag sequence) will have a restriction site and will be restricted by the enzyme. Cleavage of these oligonucleotides will avoid their amplification in subsequent steps since the primer sequences at both ends of the oligonucleotides have been separated by the cleavage. The tag sequences which are collected in the negative selection step are complementary to the tag sequences in the mixture from which oligonucleotides should be "fished out". Where the oligonucleotide to be fished out is an RNA oligonucleotide, e.g. the oligonucleotide is a ribozyme, the complementary tag sequence used for fishing out is preferably a DNA sequence. Similarly, where the oligonucleotide to be fished out is a DNA oligonucleotide, e.g. being a catalytic DNA molecule or an aptamer, the complementary tag sequence used for fishing out of such oligonucleotides is an RNA sequence. Obtaining DNA or an RNA tag sequence for such "fishing" may be by a variety of suitable amplification techniques such as
DNA polymerization, reverse transcription, and RNA transcription processes.
A specific utility of the method of the invention is in preparing ribozymes which are capable of featuring their catalytic activity only when they have a complete structure (hereinafter: "full form "), and cannot feature the activity when nicked (i.e. the sequence is non-continuous), when having a missing portion or when attached to a redundant sequence (which is a sequence that should be removed in order to render the ribozyme active) (hereinafter: "incomplete form "). Such ribozymes can be used as part of a ribozyme amplification cascade, for example, as that described in PCT Application No. PCT/US96/02380 and corresponding Israel Patent Applications Nos. 112799 and 115772 the context of which are being incorporated herein by reference. Briefly, in these patent applications, once a first, initiation ribozyme has been produced, for example due to the presence of an assayed agent in the medium, it can activate other, initially inactive ribozymes, which in turn activate further inactive ribozymes, in a self-amplificatory positive feed-back manner, which produces in a very short time an easily detectable signal. By one mode disclosed in these patent applications, the initially inactive ribozyme is either nicked, has a missing portion or comprises a nick and a redundant sequence, and only upon ligation, gap filling or splicing, respectively, it becomes catalytically active, and may in turn activate other ribozymes in the amplification cascade. In preparing such ribozymes by in vitro evolution, it is important to ensure that no catalytic activity is present prior to ligation, gap filling or splicing, in order to avoid a false positive response. An in vitro evolution method for preparing such catalytic ribozyme constitute a third embodiment in accordance with the invention. The invention provides in accordance with this embodiment an in vitro evolution method for obtaining oligonucleotides which feature a catalytic activity, but which do not feature the catalytic activity when being defective by having a nick or missing a portion in their sequence, the method comprising: (a) preparing a mixture of different oligonucleotides each of which comprises a tag sequence and at least one variable sequence, the variable sequence being a candidate sequence for evolving into a sequence which together with a conserved sequence, identical in all oligonucleotides in the mixture, will feature the catalytic activity; the variable sequence and the tag sequence being different in different oligonucleotides in the mixture, the variable sequence and the tag sequence being linked by at least one cleavable sequence;
(b) processing the oligonucleotide mixture of step (a), in two different manners so as to give rise, together with an oligonucleotide which comprise said conserved sequence, two oligonucleotide constructs, for each of the oligonucleotides in said mixture, the constructs consisting of:
(ba) a first oligonucleotide construct comprising the oligonucleotide obtained in step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence, the construct being incomplete by having a nick or a missing portion, and
(bb) a second oligonucleotide construct comprising the oligonucleotides of step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence without a nick or a missing portion; (c) carrying out a negative selection step comprising: (ca) contacting said first oligonucleotide constructs with a substrate for catalytic activity under conditions enabling said catalytic activity and removing oligonucleotide constructs which do not feature said catalytic activity thereby obtaining a first selected mixture; (cb) amplifying said first selected mixture to obtain a first amplified mixture comprising a plurality of copies of each oligonucleotide constructs;
(cc) cleaving the at least one cleavable sequence in the oligonucleotide constructs of said first amplified mixture, separating between the variable and tag sequences and collecting the tag sequences;
(d) carrying out a positive selection step comprising: contacting said second oligonucleotide construct with substrate for said catalytic activity under conditions enabling said catalytic activity and removing the oligonucleotide constructs which do not feature the catalytic activity in the presence of said substrate thereby obtaining a second selected mixture;
(e) amplifying said second selected mixture to obtain a second amplified mixture comprising a plurality of copies of each oligonucleotide construct; (f) contacting the collected tag sequences obtained from step (cc) with the second amplified mixture under stringent conditions of hybridization and removing hybridized oligonucleotide constructs from other oligonucleotide constructs of the amplified selected mixture, thereby obtaining a third selected mixture of oligonucleotide constructs featuring said catalytic activity and being essentially devoid of oligonucleotides which feature catalytic activity when present in nicked form, when missing a portion, or containing a nick together with a redundant portion.
The catalytic activity of the oligonucleotides according to this specific embodiment may be either ligation, splicing, cleavage, gap filling, kinase-like activity, biotynilation and any other catalytic activity.
In the following the present invention will be illustrated with reference to some non-limiting drawings and examples. BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows a schematic representation of the method of the invention for preparing an oligonucleotide which features catalytic activity only in the presence of an assayed agent (Fig. 1 A shows the initial steps of the method and Fig. IB subsequent steps); and
Fig. 2 shows a schematic representation of a method for preparing oligonucleotides which feature catalytic activity only when present in a full, i.e. non-defective form.
EXAMPLES
In the following Examples, the numbers in brackets indicate the number of the relevant step in the respective figure. In the drawings, DNA sequences are represented by a straight line and RNA sequences by a wavy line. Two complementary sequences are marked by the same letters one of them also marked with an apostrophe ('"").
Example 1 In vitro evolution where the selected condition is the presence of an assayed agent i. Preparing random panel of nucleic acid sequences (1)
A panel of DNA oligonucleotides is prepared on a standard nucleic acid synthesizer using a program for generating desired sequences.
A typical oligonucleotide is shown in Fig. 1, (1) and comprises a promoter (P) of about 20 bases, a substrate sequence S which can be cleaved in cis by a catalytically active oligonucleotide, a first primer for PCR amplification (PCR1), a first restriction site Cx of about 4-8 bases, a random tag (TAG) sequence of about 15 bases, a second restriction site C2 of about 4-8 bases (both and C2 sequences are constant and not random), a variable sequence (V) of 50-8000 b.p. averaging at 100, the variable sequence being a candidate for evolving to a functional sequence and a second PCR primer sequence (PCR2). The variable sequence may be a sequence derived from a sequence known to have the desired function, e.g. catalytic activity. For example, it may be a sequence obtained by doping the known sequence, at a certain degree of randomness, with other nucleic acid residues than in the original sequence. If the variable sequence is obtained by doping of a functional sequence, there may be some degree of similarity in the variable sequence between different oligonucleotides in a mixture of such oligonucleotides.
ii. Preparation of immobilized nucleic acid sequences (2 and 3)
The DNA sequences of i. above, are transcribed, using a primer with biotin (B) at the 5' end (2). The biotin, is then allowed to react with avidin which is present on a solid support, such as Strepravidin beads (SA), so that each oligonucleotide of the panel becomes immobilized onto a solid support (3).
iii. Positive selection step (4)
The specific assayed agent which is a protein (Pro) is then added to the reaction mixture (4(a)).
Magnesium and/or other co-factors required for catalytic activity, are then added to the reaction mixture in order to allow for the catalytic cis cleavage activity of the variable sequences of the oligonucleotides on substrate sequence S.
The oligonucleotide sequences in the medium may be divided into three classes, as shown (4(b)):
Class i. oligonucleotides activated only upon formation of a catalytic complex with the Pro and cleave substrate sequence S and are thus released to the medium; Class ii. oligonucleotides, which feature catalytic activity even without the protein; Class iii. (consisting of the majority of the nucleic acid sequences) oligonucleotides which do not feature a catalytic activity at all. The last step of the positive selection comprises collecting of those oligonucleotides which were freed from the immobilized beads (Class i and Class ii).
iv. Amplification of separated sequence (5)
If desired, protein attached to the oligonucleotides can be removed by denaturation through heating or by phenol extraction followed by chloroform extraction.
Sequences collected in step 4 above are reversed transcribed and amplified by PCR. Since substrate sequence S was cleaved (step 4b) this sequence should be reconstructed by using, both in the case of reverse transcription and of PCR, primers which contain the sequence of the cleaved substrate and thus the amplified and reconstructed product is again identical to (1). The amplified products are transcribed, bound to biotin and attached to a solid support as specified above (step 6).
v. Negative selection step (7)
The amplified and immobilized oligonucleotides of step 6 are subjected to a negative selection step. In this step the catalytic activity is determined either with no assayed agent, or in the presence of a non- assayed agent, which, although not identical, closely resembles the assayed agent (preferably such a non-assay agent may be one which can be encountered by the oligonucleotide in the assayed conditions); the non- assayed agent illustrated here is a protein - Pro' (step 7a); magnesium and/or other co-factors required for catalytic activity are added (step 7b). The oligonucleotides released to the medium by cleavage of the substrate sequence S belong to three classes:
Class i. in which the non-assayed agent brought about cleavage of substrate sequence; Class ii. which includes oligonucleotides cleaved with no need for any external agent whatsoever; and Class iii. which are not cleaved at all. Both Classes i. and ii. are collected (step 7c) and the protein is removed (step 7d). The sequences are reversed transcribed and amplified by PCR in order to produce a double-stranded construct (step 8). Suitable restriction enzymes are added in order to cleave sequences and C2, one cleavage site forming a blunt end and one a sticky end (step 9). The sticky end is completed with a biotinated nucleotide and then the separated TAG sequence is immobilized on a solid support (through an immobilized avidin) and denaturated so that there remains a single-stranded denaturated immobilized tag sequence. The immobilized tag sequences of step 10 are brought into contact with oligonucleotides collected of step 4(b) (Class i and Class ii) (step 11). Molecules of said group which hybridize with the immobilized TAG sequence are removed (step 12) so there remain only molecules which feature cleavage in the presence of an assayed agent (Pro) and do not feature cleavage activity without any agent or in the presence of a non- assayed agent (Pro').
The oligonucleotides obtained in step 11 are subjected again to all preceding steps for 2-1000 cycles, preferably 10-100 cycles, most preferably 20-30 cycles. Reference is now made to Fig. 2, which shows another embodiment of the in vitro evolution method of the invention. The purpose of the method disclosed in Fig. 2 is to produce oligonucleotides which are devoid of catalytic activity in an incomplete form and are capable of catalytic activity only when in a complete form. An oligonucleotide which is in an incomplete form includes an oligonucleotide with a nick in its sequence, an oligonucleotide with a missing nucleotide segment, an oligonucleotide with a nick and with a redundant sequence, etc.
A mixture of different DNA sequences 1 is prepared (step a) featuring (from 5'→3'): immobilization moiety (such as a bead), linked to a promoter (PROM), a first PCR primer (PCR1'), a variable sequence V,', a cleavage sequence Cj, tag sequence (TAG), a cleavable sequence C2, another variable sequence V2' and a second PCR primer (PCR2'). Vx' and V2' are both sequences which are complementary to doped sequences from an original Group I ribozyme (hereinafter "known ribozyme") and comprise together only a part (for example, half) complementary to that known ribozyme. The TAG sequence between V, and V2' is present within a sequence coding for an intron of the known ribozyme and thus does not interfere with the activity of the transcript.
DNA sequence 1 is processed by two routes: First by Route I (left) which brings about production of nicked oligonucleotides for negative selection purposes and second by Route II (right) which brings to production of complete oligonucleotides.
In Route I, the DNA sequence 1 is transcribed by T7 polymerase to result in transcript 2 (step b). Transcript 2 is then brought into contact with an RNA oligonucleotide 3 comprising a sequence denoted "CONS " which is a conserved sequence of the known ribozyme required to complete the doped parts Vx and V2 (transcribed from V/ and V2') to a complete ribozyme, (so that Vx+V2+CONS constitute together a construct resembling that of the known ribosome wherein the 5 '-end part (V,+V2) is doped (as compared to a known ribozyme) and the 3'-end part (CONS) is identical to a known ribozyme).
Transcript 2 and oligonucleotide 3, hybridize to form together construct 4, (step c) which is essentially similar to the known ribozyme (with doped V, and V2 sequences and conserved CONS) but having a nick 5. The purpose of the method of the invention according to this embodiment is to remove all species of oligonucleotides which feature catalytic activity despite having a nick - i.e. to remove all species represented by construct 4.
Oligonucleotides which serve as substrates for ligation and which are immobilized to a solid support 6 are then added to construct 4, and the two are allowed to ligate (step d). The construct 4 fall into two classes (step e): Class (1) constructs which were able to ligate to the immobilized substrate and are thus collected and Class (2) constructs which were not able to ligate, remain soluble and are thus removed. Separation can also be carried out, mutatis mutandis, utilizing cleavage activity, gap filling, splicing activities, etc. The collected constructs are reverse transcribed and amplified utilizing PCR primers PCR1 and PCR2 (the CONS sequence is thus not amplified) and the TAG sequence are removed therefrom, for example by restriction enzymes (step f). The TAG is then immobilized to a solid support to yield immobilized tag 11, which will be used to "fish out" species which should be removed (step g).
In Route II, DNA recovered after reverse transcription and amplification in step (f) of route II (which is identical to DNA sequence 1) or the DNA sequence 1 itself is brought into contact with DNA oligonucleotide 7 having PCR2 sequence complementary to PCR2', CONS' of coding for a conserved sequence as described above and PCR3 sequence which complements to a third PCR primer (step h). The two are allowed to hybridize and in the presence of DNA polymerase and nucleotides give rise to double-stranded DNA construct 8 (step i) which in the presence of T7 polymerase brings to the production of transcript 9 (step j). Transcript 9 is in essence identical to construct 4 but it does not have a nick.
Oligonucleotide substrate 6 is then added. Those transcripts 9 which were able to ligate to substrate 6 are maintained (class 1) and those which were not able to are removed (class 2) (step k). The maintained transcripts are reverse transcribed and PCR amplified to give transcripts 10 (step 1).
Transcripts 10 are contacted with immobilized TAG 11 obtained in step g in a negative selection step (step m). Those transcripts 10 which hybridize with the TAG are then removed (step n). By the method of Fig. 2, it is thus possible to use the same pool of oligonucleotides 1, for two separate selections - a negative selection step which removes oligonucleotides which are catalytically active when present with a nick and a positive selection step which selects for oligonucleotides showing catalytic activity without a nick.

Claims

CLAIMS:
1. An in vitro evolution method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, and which do not feature the desired property under a set of conditions different than the selected set of conditions, said desired property being imparted by a functional sequence of said oligonucleotides, the method comprising:
(a) preparing a mixture of different oligonucleotides each comprising a variable sequence, derived from a functional sequence of an oligonucleo- tide, known to feature said desired property under a selected set of conditions, and a tag sequence; said variable sequence and said tag sequence being different in different oligonucleotides in the mixture, said variable sequence and said tag sequences being linked by at least one cleavable sequence; (b) applying a second set of conditions being different than said selected set of conditions and separating between a first group of oligonucleotides which do not feature the desired property under said second set of conditions and a second group of oligonucleotides featuring said desired property under said second set of conditions, to obtain a first selected mixture comprising said first group of oligonucleotides and a second selected mixture comprising said second group of oligonucleotides;
(c) amplifying said second group of oligonucleotides in said second selected mixture to produce a plurality of copies of each of said second group of oligonucleotides to obtain a first amplified mixture; (d) cleaving the cleavable sequence of the oligonucleotides in the first amplified mixture, separating between the variable and the tag sequences and collecting the tag sequences;
(e) contacting the collected tag sequences with the first selected mixture under stringent conditions of hybridization and removing hybridized oligonucleotides from other oligonucleotides of the second mixture; thereby obtaining a third selected mixture of oligonucleotides essentially devoid of oligonucleotides which feature the desired property under a set of conditions different than the selected set of conditions.
2. An in vitro evolution method for obtaining oligonucleotides which feature a desired property under a selected set of conditions, and which do not feature the desired property under a set of conditions different than the selected set of conditions, said desired property being imparted by a functional sequence of said oligonucleotides, the method comprising:
(a) preparing a mixture of different oligonucleotides each of which comprises a variable sequence being a candidate for said functional sequence and a tag sequence, said variable sequence and said tag sequence being different in different oligonucleotides in the mixture, the variable sequence and the tag sequence being linked by at least one cleavable sequence;
(b) processing the mixture through positive and negative selection steps, there being at least one positive selection step and at least one negative selection step, these steps comprising:
(ba) a positive selection step comprising applying said selected set of conditions and separating between oligonucleotides which feature said desired property and those which do not, to obtain a first selected mixture comprising a first group of oligonucleotides featuring said desired property under said selected set of conditions;
(bb) an amplification step comprising amplifying said first group of oligonucleotides in said first selected mixture to produce a plurality of copies of each of said first group of oligonucleotides to obtain a first amplified mixture; (be) a negative selection step comprising:
(bca) applying a second set of conditions, being different than said selected set of conditions, and separating between a second group of oligonucleotides which do not feature the desired property under said second set of conditions and a third group of oligonucleotides featuring said desired property under said second set of conditions, to obtain a second selected mixture comprising said second group of oligonucleotides and a third selected mixture comprising said third group of oligonucleotides; (bcb) amplifying said third group of oligonucleotides in said third selected mixture to produce a plurality of copies of each of said third group of oligonucleotides to obtain a second amplified mixture;
(bcc) cleaving the cleavable sequence of the oligonucleotides in the second amplified mixture, separating between the variable and the tag sequences and collecting the tag sequences;
(bed) contacting the collected tag sequences with the second selected mixture under stringent conditions of hybridization and removing hybridized oligonucleotides from other oligonucleotides of the second mixture, thereby obtaining a fourth selected mixture of oligonucleotides essentially devoid of oligonucleotides which feature the desired property under a set of conditions different than the selected set of conditions; where said positive selection step precedes said negative selection step, said positive selection step is applied on said mixture prepared in step (a) and said negative selection step is applied on said first amplified mixture; and where said negative selection step precedes said positive selection step, said negative selection step is applied on said mixture obtained in step (a) and said positive selection step is applied on said fourth mixture.
3. A method according to Claim 2, wherein said positive selection step precedes said negative selection step, and wherein the method comprises a plurality of negative selection steps, each subsequent negative selection step being applied on said fourth mixture obtained in a previous negative selection step.
4. A method according to any one of the preceding claims, wherein said desired property is a catalytic activity.
5. A method according to any one of the preceding claims, wherein said selected set of conditions comprises the presence of an assayed agent in the medium.
6. A method according to Claim 5, wherein said agent is a nucleic acid sequence or a macromolecule.
7. A method according to Claim 1, wherein the collected TAG sequences of step (d) are DNA sequences and the oligonucleotides in the mixture of step (a) are RNA sequences.
8. A method according to Claim 2, wherein the collected TAG sequences of step (bcc) are DNA sequences and the oligonucleotides in said first amplified mixture are RNA sequences.
9. An in vitro evolution method for obtaining oligonucleotides which feature a catalytic activity, but which do not feature the catalytic activity when being defective by having a nick or missing a portion in their sequence, the method comprising:
(a) preparing a mixture of different oligonucleotides each of which comprises a tag sequence and at least one variable sequence, the variable sequence being a candidate sequence for evolving into a sequence which together with a conserved sequence, identical in all oligonucleotides in the mixture, will feature the catalytic activity; the variable sequence and the tag sequence being different in different oligonucleotides in the mixture, the variable sequence and the tag sequence being linked by at least one cleavable sequence;
(b) processing the oligonucleotide mixture of step (a), in two different manners so as to give rise, together with an oligonucleotide which comprise said conserved sequence, two oligo-nucleotide constructs, for each of the oligonucleotides in said mixture, the constructs consisting of: (ba) a first oligonucleotide construct comprising the oligonucleotide obtained in step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence, the construct being incomplete by having a nick or a missing portion, and (bb) a second oligonucleotide construct comprising the oligonucleotides of step (a) or a transcription product thereof and an oligonucleotide comprising said conserved sequence without a nick or a missing portion;
(c) carrying out a negative selection step comprising:
(ca) contacting said first oligonucleotide constructs with a substrate for catalytic activity under conditions enabling said catalytic activity and removing oligonucleotide constructs which do not feature said catalytic activity thereby obtaining a first selected mixture;
(cb) amplifying said first selected mixture to obtain a first amplified mixture comprising a plurality of copies of each oligonucleotide constructs; (cc) cleaving the at least one cleavable sequence in the oligonucleotide constructs of said first amplified mixture, separating between the variable and tag sequences and collecting the tag sequences;
(d) carrying out a positive selection step comprising: contacting said second oligonucleotide construct with substrate for said catalytic activity under conditions enabling said catalytic activity and removing the oligonucleotide constructs which do not feature the catalytic activity in the presence of said substrate thereby obtaining a second selected mixture;
(e) amplifying said second selected mixture to obtain a second amplified mixture comprising a plurality of copies of each oligonucleotide construct;
(f) contacting the collected tag sequences obtained from step (cc) with the second amplified mixture under stringent conditions of hybridization and removing hybridized oligonucleotide constructs from other oligonucleotide constructs of the amplified selected mixture, thereby obtaining a third selected mixture of oligonucleotide constructs featuring said catalytic activity and being essentially devoid of oligonucleotides which feature catalytic activity when present in nicked form, when missing a portion, or containing a nick together with a redundant portion.
10. An oligonucleotide obtained by the method of any one of
Claims 1-9.
PCT/IL1997/000283 1997-03-17 1997-08-26 In vitro evolution of oligonucleotides WO1998041654A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU38621/97A AU3862197A (en) 1997-03-17 1997-08-26 (in vitro) evolution of oligonucleotides
JP54028898A JP2001515358A (en) 1997-03-17 1997-08-26 In vitro evolution of oligonucleotides
EP97935737A EP0970241A1 (en) 1997-03-17 1997-08-26 (in vitro) evolution of oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12046697A IL120466A0 (en) 1997-03-17 1997-03-17 In vitro evolution of oligonucleotides
IL120466 1997-03-17

Publications (1)

Publication Number Publication Date
WO1998041654A1 true WO1998041654A1 (en) 1998-09-24

Family

ID=11069933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1997/000283 WO1998041654A1 (en) 1997-03-17 1997-08-26 In vitro evolution of oligonucleotides

Country Status (5)

Country Link
EP (1) EP0970241A1 (en)
JP (1) JP2001515358A (en)
AU (1) AU3862197A (en)
IL (1) IL120466A0 (en)
WO (1) WO1998041654A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011206056A (en) * 1999-01-07 2011-10-20 Medical Research Council Optically sorting method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009158A1 (en) * 1992-10-14 1994-04-28 University Research Corporation Method for selecting nucleic acids on the basis of structure
WO1996027026A1 (en) * 1995-02-27 1996-09-06 Intelligene Ltd. Detection of biomolecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009158A1 (en) * 1992-10-14 1994-04-28 University Research Corporation Method for selecting nucleic acids on the basis of structure
WO1996027026A1 (en) * 1995-02-27 1996-09-06 Intelligene Ltd. Detection of biomolecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KLUG S J ET AL: "ALL YOU WANTED TO KNOW ABOUT SELEX", MOLECULAR BIOLOGY REPORT, vol. 20, no. 2, 1994, pages 97 - 107, XP000617781 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011206056A (en) * 1999-01-07 2011-10-20 Medical Research Council Optically sorting method

Also Published As

Publication number Publication date
JP2001515358A (en) 2001-09-18
AU3862197A (en) 1998-10-12
EP0970241A1 (en) 2000-01-12
IL120466A0 (en) 1997-07-13

Similar Documents

Publication Publication Date Title
AU717736B2 (en) Catalytic nucleic acid and its medical use
US6387620B1 (en) Transcription-free selex
US5637459A (en) Systematic evolution of ligands by exponential enrichment: chimeric selex
JP6336443B2 (en) Target detection and signal amplification
JP6557151B2 (en) Method for sequencing nucleic acids in a mixture and compositions related thereto
JPH11507219A (en) Catalytic DNA
CN107532219B (en) Solid phase target nucleic acid capture and replication using strand displacement polymerase
EP1907410B1 (en) Methods for the selection of aptamers
US6207388B1 (en) Compositions, methods, kits and apparatus for determining the presence or absence of target molecules
JPH10510165A (en) DNA enzyme molecule
KR20210104555A (en) Primer oligonucleotides for sequencing
WO1998041654A1 (en) In vitro evolution of oligonucleotides
EP2333102A1 (en) Method for identifying RNA ligands
CN114364813B (en) Method for multiplex isothermal amplification of nucleic acid sequences
WO2024028589A1 (en) Bead-hashing
US20020018994A1 (en) Continuous in vitro evolution of oligonucleotides
AU2022280886A1 (en) Oligo-modified nucleotide analogues for nucleic acid preparation
IL119135A (en) Catalytic nucleic acid molecules
MXPA99001950A (en) Catalytic nucleic acid and its medical use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997935737

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 540288

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09381196

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997935737

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997935737

Country of ref document: EP